Cerecor Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CERC
  • 1d0.92%
  • 1w-1.79%
  • 1m-8.71%
  • 1y-2.22%
ATH
  • ATH Price$7.22
  • ATH Date2019-02-27
  • % since ATH-69.53%
  • % to ATH228.18%
ATL
  • ATL Price$0.44
  • ATL Date2017-04-28
  • % from ATL397.74%
  • Last Low Price$1.7
  • Last Low Date2020-03-16
  • % From Last Low29.41%
IPO
  • IPO Price$4.95
  • % Current ROI USD-55.56%
  • ATH Price$7.22
  • % ROI ATH 163,348.42%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CERC"]

Key Data [addtoany]

Current price $2.2
Sector Healthcare
Industry Biotechnology
Today's High/Low $2.23/$2.12
Volume 333,049.00
Previous Close $2.18
52 Week High/Low $4.5/$1.98
Market Cap 284,989,664.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0
Annualized Dividend $0
$2.2
[addtoany]

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases.
The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803.
It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn’s diseases.
In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation.
The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity